OLD National Bancorp IN Has $623,000 Stock Position in Becton, Dickinson and Company $BDX

Key Points

• OLD National Bancorp IN reduced its stake in Becton, Dickinson and Company by 31.2%, owning 3,614 shares valued at $623,000 as of the latest SEC filing.
• Becton, Dickinson reported a 10.4% year-over-year revenue increase in its latest quarter, achieving $5.51 billion in revenue and exceeding EPS estimates by $0.28.
• The company recently declared a quarterly dividend of $1.04, representing an annualized yield of 2.2% with a payout ratio of 74.82%.

OLD National Bancorp IN cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 31.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,614 shares of the medical instruments supplier's stock after selling 1,639 shares during the period. OLD National Bancorp IN's holdings in Becton, Dickinson and Company were worth $623,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at about $26,000. Smallwood Wealth Investment Management LLC bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC increased its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company in the first quarter worth $31,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $191.94 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The firm has a market cap of $55.02 billion, a price-to-earnings ratio of 34.52, a price-to-earnings-growth ratio of 1.51 and a beta of 0.25. The stock's 50-day moving average is $189.21 and its 200-day moving average is $186.79. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the company earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BDX. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Morgan Stanley boosted their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Weiss Ratings restated a "hold (c-)" rating on shares of Becton, Dickinson and Company in a report on Saturday, September 27th. Piper Sandler reiterated a "neutral" rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Argus boosted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $205.40.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,023 shares of company stock valued at $562,036 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.